Kuros Biosciences
- Company typePublic
- Founded2000
- HeadquartersSchlieren, Switzerland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Kuros Biosciences firmographics
Firmographics- Name
- Kuros Biosciences
- Legal name
- Kuros Biosciences A.G.
- Website
- https://kurosbio.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Kuros Biosciences industry classification
Industry- Product category
- Bone Graft Substitutes
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Kuros Biosciences is headquartered
LocationHeadquarters
- HQ city
- Schlieren
- HQ country
- Switzerland
- HQ region
- Europe
Offices4 records
Markets served
Kuros Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- MagnetOs Bone Graft Product Sales: Sale of MagnetOs family of bone graft products including Granules, Putty, Easypack Putty, Flex Matrix, and MIS delivery systems. Revenue derived from direct commercial sales in US and Europe, plus distribution sales in APAC and other international markets.
- Spinal Fusion Biologics: Development and commercialization of spinal fusion biologics including MagnetOs and Fibrin-PTH products for spinal fusion procedures.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | No publicly listed pricing available |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Kuros Biosciences product offering
Product offeringCore offering
Kuros Biosciences develops and commercializes synthetic bone graft substitute products, marketed under the MagnetOs brand, used in spinal fusion and other orthopedic procedures. The products are designed to support bone healing and fusion in patients undergoing surgical procedures of the spine and extremities. The company also advances a research-stage Fibrin-PTH program for spinal fusion.
Product overview
Kuros Biosciences is a Swiss-headquartered biotech company that has developed MagnetOs, a comprehensive bone graft platform built around the proprietary NeedleGrip submicron surface technology. The platform includes multiple product formulations: MagnetOs Granules (foundational granules), MagnetOs Putty, MagnetOs Flex Matrix, MagnetOs MIS delivery system, and MagnetOs Easypack Putty. All MagnetOs products harness the immune system to stimulate bone growth without added cells or growth factors. The company also maintains Fibrin-PTH in Phase 2 clinical trials and supports its products with extensive clinical evidence through the Project Fusion research program. Products target spine surgery (posterolateral fusion, interbody fusion, minimally invasive procedures), extremities (foot and ankle), trauma, and oncology applications.
Differentiator
Problem solved
Functional benefit
Brands
- MagnetOs: Bone graft product line powered by NeedleGrip submicron surface technology for spinal fusion, extremities, and trauma applications
- NeedleGrip
- Project Fusion
Products and services
- MagnetOs Granules
Quantifiable outcome
- 79% fusion rate vs 47% autograft in Level I randomized controlled trial (128 evaluated spinal levels in 91 patients)
- +5 more outcomes
Companies that use Kuros Biosciences
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
Kuros Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Kuros Biosciences partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- MedtroniccoreExclusive strategic agreement with Medtronic spinal division for distribution of MagnetOs products. Announced January 2025 by Kuros Biosciences USA, Inc.
- Middle East Distribution PartnersminorLaunch of MagnetOs in Middle East countries announced October 2024 through distribution partnerships.
- Top 3 Spine CompanycoreSales distribution agreement with a top 3 spine company announced August 2023.
- APAC DistributorminorFirst APAC distributor agreement signed July 2019 for distribution of MagnetOs products in Asia-Pacific markets.
- NovartisminorCollaborations with major pharmaceutical firms including Novartis for research and development on Immunodrugs.
- PfizerminorCollaborations with major pharmaceutical firms including Pfizer for research and development on Immunodrugs.
- Xpand BiotechnologycoreAcquired Xpand Biotechnology in January 2017 to strengthen the biologics platform, which became the foundation for MagnetOs technology.
Scale indicators8 records
Recent moves10 records
Expansion highlights6 records
Kuros Biosciences competitors and assessment
Company assessmentDirect peers
- NuVasive (now Globus Medical): Post the Globus Medical merger, NuVasive/Globus is one of the top 3 spine companies Kuros referenced in its August 2023 distribution deal. It sells a comprehensive spine hardware and biologic portfolio and competes for the same surgeon call points and operating-room minutes as MagnetOs.
- Orthofix Medical: Orthofix (which merged with SeaSpine) sells spine hardware and a bone growth stimulator portfolio, with overlapping surgeon customers in spine fusion. Kimberley Elting (Kuros board) was previously President of Global Orthopedics at Orthofix, indicating close strategic and customer overlap.
- Medtronic (Spinal Division): Medtronic's spinal division is both Kuros's exclusive distributor (January 2025) and a direct competitor via its Infuse (rhBMP-2) bone graft franchise. Both serve spine fusion surgeons with biologic bone grafting solutions and compete for the same hospital purchasing decisions.
- MTF Biologics: MTF Biologics is a major tissue bank selling allograft-based bone graft substitutes (e.g., OsteoStrux, DBX) directly competitive with MagnetOs in spinal fusion. Together with Bonesupport, MTF represents the two principal competitive axes vs. Kuros's synthetic alternative — allograft vs. synthetic.
- Bonesupport Holding: Sweden-based Bonesupport markets CERAMENT, a synthetics-based bone graft substitute for trauma, revision arthroplasty and osteomyelitis. It is one of the closest direct competitors to MagnetOs in the synthetic, growth-factor-free orthobiologics category and competes for similar hospital budgets.
Broad incumbents
- DePuy Synthes (Johnson & Johnson): DePuy Synthes is J&J's orthopedic/spine franchise and a major seller of bone graft substitutes and spine hardware globally. Multiple Kuros leaders (I.V. Hall, John Griffin, Joe Ross, Todd Stohler) are ex-DePuy, underscoring the technology/sales overlap and competing for similar accounts.
- Integra LifeSciences: Integra LifeSciences sells regenerative medicine and orthopedic products (including Acera biologics and DuraGen dural repair) to spine, neurosurgery and trauma surgeons. Its portfolio overlaps with Kuros's extremities and trauma aspirations and targets the same hospital value analysis committees.
- Stryker (Spine): Stryker's spine business (formerly Stryker Spine, including acquired Vitera and Vertos) sells bone graft substitutes and spine hardware to the same surgeon base as Kuros. VP US Sales Todd Stohler is an ex-Stryker Spine leader, illustrating the talent and competitive overlap.
Emerging players
- Baxter International (Tisseel/Veraseal): Baxter's surgical sealants and hemostats compete adjacently with Fibrin-PTH (Kuros's Phase 2 fibrin-based biologic). Baxter also sells biologic adjuncts in spine and orthopedics, and its fibrin-based franchise makes it the most relevant pharma/medtech peer for Fibrin-PTH's eventual commercial market.
Regional players
- ZimVie (Spine Division): ZimVie's Spine division (formerly Zimmer Biomet Spine) sells bone graft and spinal hardware products with overlapping surgeon relationships; Joe Ross (Kuros SVP Marketing) was previously GM of Zimmer Biomet's global Spine division. While smaller post-spinoff, ZimVie is a comparable peer in spine biologics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Kuros Biosciences social profiles
Digital presenceKuros Biosciences compliance and trust
Trust signalCompliance1 record
Kuros Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kuros Biosciences leadership team
Management profileNumber of profiles
Kuros Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Kuros Biosciences funding detail
Funding detailFunding overview
Funding rounds9 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kuros Biosciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kuros Biosciences
What does Kuros Biosciences do?
Kuros Biosciences develops and commercializes synthetic bone graft substitute products, marketed under the MagnetOs brand, used in spinal fusion and other orthopedic procedures. The products are designed to support bone healing and fusion in patients undergoing surgical procedures of the spine and extremities. The company also advances a research-stage Fibrin-PTH program for spinal fusion.
Is Kuros Biosciences a public or private company?
Kuros Biosciences is a public company. It is classified as public and is currently operating.
When was Kuros Biosciences founded?
Kuros Biosciences was founded in 2000. It employs 101 to 250 people.
Where is Kuros Biosciences based?
Kuros Biosciences is headquartered in Schlieren, Switzerland, in the Europe region.
How does Kuros Biosciences make money?
Two revenue lines are on record. MagnetOs Bone Graft Product Sales are the primary driver. The others are spinal Fusion Biologics.
Who are Kuros Biosciences's main competitors?
Direct peers on record are NuVasive (now Globus Medical), Orthofix Medical, Medtronic (Spinal Division), MTF Biologics and Bonesupport Holding. Broad incumbents are DePuy Synthes (Johnson & Johnson), Integra LifeSciences and Stryker (Spine). Baxter International (Tisseel/Veraseal) is listed as an emerging player. ZimVie (Spine Division) is listed as a regional player.
Does Kuros Biosciences have an API?
No public API is recorded for Kuros Biosciences.
What industry is Kuros Biosciences in?
Kuros Biosciences's product category is Bone Graft Substitutes. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHAEAC, Spine Implants & Motion Preservation (Fusion/Disc/Interspinous). Its NAICS code is 325414 and its SIC code is 3842.